Skip to content

Clinical study of Guoben Cough and Asthma Granules in the treatment of patients with stable chronic obstructive pulmonary disease (deficiency of Qi in the lungs and kidneys)

Clinical study of Guoben Cough and Asthma Granules in the treatment of patients with stable chronic obstructive pulmonary disease (deficiency of Qi in the lungs and kidneys)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000860
Enrollment
Unknown
Registered
2024-12-22
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

experimental group:Western medicine conventional treatment combined with Gu Ben Cough Granules
control group:Western medicine

Sponsors

The Third Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Meet the western medical diagnostic criteria for COPD in the stable stage E group; 2) Meet the diagnostic criteria for COPD in Chinese medicine deficiency of lung and kidney; 3) In the clinically stable stage of COPD no respiratory infections and AECOPD in the last 4 weeks; 4) 18 years old = age = 80 years old gender is not limited; 5) Voluntary acceptance of treatment. 5) Voluntarily accept the treatment and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with airflow limitation due to asthma bronchiectasis pulmonary fibrosis; 2) Those who have undergone lung transplantation or lung resection; 3) Those who suffer from severe hypertension heart failure arrhythmia diabetes mellitus primary cardiac hepatic renal hematological and neurological symptoms etc. which are not under control; 4) Those who suffer from lung tumors malignant tumors (<5 years from the time of initial diagnosis or the presence of imaging or tumor markers and other tests to confirm the presence of recurrence metastasis or undergoing radiotherapy chemotherapy targeted therapy immunotherapy etc.); 5) Those who are allergic to known drug components; 6) Pregnant women women who are planning to be pregnant or breastfeeding; 7) Patients who are not considered suitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Diaphragmatic ultrasound indices: diaphragm thickness (TDI) diaphragm mobility (DE) diaphragm inspiratory thickening fraction (TFdi) and diaphragm stiffness changes;Immune indicators (CD4+ CD8+ CD4+/CD8+);

Secondary

MeasureTime frame
Pulmonary Function Assessment(FEV1\FVC\FEV1/FVC);Self-assessment test for patients with chronic obstructive pulmonary disease;Chinese Medicine Score;

Countries

China

Contacts

Public ContactLou LIming

Zhejiang Zhongshan Hospital

2825994609@qq.com13505712348

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026